China’s Harbour BioMed has launched a new biotech to develop bispecific antibodies focused on the holy grail of next-gen obesity meds—reducing body weight without losing muscle mass.

By Michael C. Bender Reporting from Washington Linda McMahon’s first act as secretary of education was to instruct staff to prepare for its “final mission,” her clearest indication yet of ...

Now, as the Executive Director of Conestee Nature Preserve, she continues her mission to protect the special places that make the Upstate unique. “What I felt called to was protecting the specia ...

The new hand luggage-compliant roller-case is available in three colorways It's part of Peak Design's ecosystem, with a new purpose-made XL Camera Cube Priced from $599.95, with crowdfunding ...